The novel galectin-3 inhibitor GB1211 reduces inflammation & fibrosis in a rabbit high fat diet model of NASH & fibrosis Poster no: 5042

Galecto


<u>Robert J. Slack¹, Paolo Comeglio², Sandra Filippi³, Giulia Guarnieri⁴, Ilaria Cellai², Luciano Adorini⁵, Annamaria Morelli⁴, Linda Vignozzi^{2,5}, Mario Maggi^{2,5}</u>

¹Galecto Biotech AB, Stevenage Bioscience Catalyst, Stevenage, UK, ²Department of Experimental & Clinical Biomedical Sciences 'Mario Serio', University of Florence, Florence, Italy, ³Department of Neurosciences, Psychology, Drug Research & Child Health (NEUROFARBA), University of Florence, Italy, ⁴Department of Experimental & Clinical Medicine, University of Florence, Italy, ⁵Istituto Nazionale Biostrutture e Biosistemi, Rome, Italy,

Background

- Galectin-3 (Gal-3) is a pro-fibrotic β -galactoside binding lectin highly expressed in fibrotic liver¹ & implicated in hepatic fibrosis² (see Diagram 1).
- GB1211 is a novel orally active Gal-3 small molecule inhibitor³ that has high affinity for Gal-3 (human $K_D = 25$ nM; rabbit $K_D = 12$ nM) & high oral bioavailability in rabbits & man.
- In this study the efficacy of GB1211 was investigated in a high fat diet (HFD) rabbit model of non-alcoholic steatohepatitis (NASH)⁴.


Diagram 1. The infection, inflammatory & injury pathways driven by galectin-3 that lead to organ fibrosis.



റ്റ **Methods** 2

- Male New Zealand White rabbits were individually caged under standard conditions in a temperature & humidity-controlled room on a 12h light/darkness cycle.
- After 1 week of regular diet (RD), rabbits were randomly assigned to 4 different groups (n=3/group): RD/vehicle, RD/30mg/kg GB1211, HFD/vehicle & HFD/30 mg/kg GB1211 (vehicle/GB1211 p.o. dosed therapeutically q.d. 5 days from week 11) for 12 weeks.
- Liver inflammation, steatosis, ballooning, & fibrosis was measured via blood metabolic markers, histomorphological analysis (Masson's trichome, Giemsa, oil red O & picrosirius red (PSR)), second generation harmonics (SHG collagen content) & fibrotic gene signature.
- Plasma concentrations of GB1211 were determined by LC-MS.

Figure 1. Study design for GB1211 in a rabbit HFD model



This work was sponsored by Galecto Inc.

References

Galecto

¹Gudowska et al., (2015). Ann Clin Lab Sci, 45, 669-673 ³Zetterberg et al., (2022) J Med Chem, 65, 12626-12638 ⁵Kleiner et al., (2005) Hepatology, 41, 1313-1321

²Henderson et al., (2006) Proc Natl Acad Sci USA, 103, 5060-5065 ⁴Comeglio et al., (2018) J Endocrinol, 238, 107-127



Figure 2. Liver weight (A), ALT (B) and AST (C) are increased from RD to HFD rabbits.

Α

wei ody

ब ब ब ब | | | | | | | Summary

GB1211 normalized inflammation & fibrosis in a HFD rabbit model of NASH & liver fibrosis following less than a week of dosing.


• Further studies to investigate a full dose response for GB1211 & further understand the concentration/response relationship is on-going to investigate 0.3 mg/kg, 1 mg/kg, 5 mg/kg & 30 mg/kg dose levels.

• The rabbit HFD model has the potential to support clinical dose selection & rationale for GB1211 with further studies to understand rabbit ADME & PK parameters on-going to complete the translational data package.

• This data supports the current ongoing phase 2b study investigating GB1211 in liver cirrhosis patients (NCT05009680 presented at AASLD in 2022 poster abstract 3627 & oral abstract 5014).

Results


Demonstration of HFD-induced disease phenotype



• Liver weight, ALT and AST VAT were all significantly increased from RD to HFD vehicle groups.


Results


state (B).




PK data

daily for 4 days. Figure 4. GB1211 reduced inflammation (Giemsa inflammatory foci score⁵) (A) & fibrosis (B (PSR), C (SHG)) in HFD rabbits to levels observed in RD rabbits with trends for reduction in mRNA levels of pro-fibrotic mediators (D). Overall assessment of all inflammatory for







Efficacy data

Acknowledgements

All work was funded by Galecto Biotech AB. PC, SF, GG, IC, AM, LV, MM: received funding from Galecto Biotech AB to complete work. AD: consultant for Galecto Biotech AB. RS: employee of Galecto Biotech AB, may hold stocks or shares.

Figure 3. Galectin-3 & collagen deposition is increased from RD to HFD rabbits (A) with GB1211 demonstrates high exposure of free drug at 30 mg/kg in RD & HFD rabbits at steady

• Marginal increase in exposure following dosing in HFD compared with RD rabbits.

• GB1211 reached steady state free plasma concentrations at C_{min} of 40 x K_D when dosed once

• Inflammation score, steatosis (binomial score & % area oil red O), ballooning score & fibrosis (% PSR, SHG) were all significantly increased from RD to HFD vehicle groups.

• GB1211 significantly reduced all measures of inflammation & fibrosis compared with the HFD/vehicle group. There were also trends for reduction in fibrotic & Gal-3 mechanistic genes (COL1A1, COL3A1, SNAI2, LGALS3, PAI-1).

• The neoepitope collagen biomarker pro-C3 was detectable in rabbit plasma & elevated between RD & HFD, though no reduction in levels was observed with GB1211 over 5 days.